Welcome to our dedicated page for Morgan Stanley SEC filings (Ticker: MS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Morgan Stanley’s disclosures are a treasure trove of information on everything from trading Value-at-Risk to the health of its $4T wealth-management franchise. But finding those details inside a 300-page report is tedious. This page curates every filing the firm submits to EDGAR, then layers Stock Titan’s AI so Morgan Stanley SEC filings are explained simply.
Need the latest Morgan Stanley quarterly earnings report 10-Q filing or an Morgan Stanley 8-K material events explained summary? We post them in real time and generate concise AI-powered breakdowns of segment revenue, capital ratios, and liquidity buffers. Curious about management’s trading activity? Our alerts track Morgan Stanley insider trading Form 4 transactions and show Morgan Stanley Form 4 insider transactions real-time, highlighting patterns before they hit the news. When proxy season arrives, the platform pinpoints pay packages inside the Morgan Stanley proxy statement executive compensation section—no more hunting through exhibits.
Professionals use these tools to:
- Compare quarter-over-quarter margins with a click using our Morgan Stanley earnings report filing analysis
- Monitor Morgan Stanley executive stock transactions Form 4 for buy-sell trends
- Read a Morgan Stanley annual report 10-K simplified summary that clarifies risk factors, legal reserves, and capital plans
- Ask natural questions like “understanding Morgan Stanley SEC documents with AI” and receive instant answers
Whether you’re gauging deal pipelines, stress-testing balance sheets, or assessing leadership’s confidence, our AI-powered summaries, expert context, and real-time updates turn raw filings into actionable knowledge—faster than opening a PDF.
Rigel Pharmaceuticals, Inc. received joint Schedule 13G/A filings from Morgan Stanley and Morgan Stanley Capital Services LLC reporting passive ownership in the company's common stock. The combined report shows 116,406 shares beneficially owned by Morgan Stanley with
ESSA Pharma Inc. filing reports that Morgan Stanley and certain MS reporting units hold 1,904,062 common shares, representing 4.0% of the outstanding class as of the event date 09/30/2025. The filing shows shared voting power of 1,876,562 shares and shared dispositive power of 1,904,062, with no sole voting or dispositive power reported. The document states Morgan Stanley has ceased to be a beneficial owner above 5% of the class. Morgan Stanley & Co. LLC separately reports 0 shares and 0.0% ownership. The filing is a routine Schedule 13G amendment disclosing passive ownership and includes exhibits for a joint filing agreement and subsidiary identification.
Morgan Stanley filed a Form 13F-HR reporting holdings as of 06-30-2025 in a combination report covering multiple affiliated managers. The filing aggregates positions from 24 other included managers, reports 44,865 information table entries and discloses a combined market value of $1,535,086,861,391. The cover page identifies the reporting manager (Morgan Stanley) and a primary contact signer (Chris O'Hara). The filing type is a 13F combination report, indicating some holdings are reported here and others are reported by affiliated managers listed on the form.
FAQ
What is the current stock price of Morgan Stanley (MS)?
What is the market cap of Morgan Stanley (MS)?
